Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation.
about
Graft vs. host disease and graft vs. myeloma effect after non-myeloablative allogeneic transplantation.Immunotherapy using dendritic cells against multiple myeloma: how to improve?Cellular immunotherapy using dendritic cells against multiple myelomaGraft-versus-host disease in mini-transplant.Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myelomaImmunotherapy in multiple myeloma--possibility or probability?Cure of multiple myeloma -- more hype, less reality.Myeloablative allogeneic stem cell transplantation for advanced stage multiple myeloma: very long-term follow up of a single center experience.The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma.Immunotherapy of multiple myeloma: the start of a long and tortuous journey.Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation.The allogeneic dilemma.A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97Role of autologous and allogeneic stem cell transplantation in myeloma.Nonabsorbable corticosteroids use in the treatment of gastrointestinal graft-versus-host disease.Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.The Relationship between STR-PCR Chimerism Analysis and Chronic GvHD Following Hematopoietic Stem Cell Transplantation.Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.Guidelines for the diagnosis and management of multiple myeloma 2011.Allogeneic hematopoietic stem cell transplantation for multiple myeloma: what place, if any?Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation.Evolving role of high dose stem cell therapy in multiple myeloma.Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.Adoptive immunotherapy with donor lymphocyte infusions and interleukin-2 after high-dose therapy and autologous stem cell rescue for multiple myeloma.Enumeration of blood dendritic cells in patients with multiple myeloma at presentation and through therapy.Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma.Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates.Plasma cell lysate as an antigen source in multiple myeloma immunotherapy.Reduced-intensity allografting in patients with therapy-related myeloid neoplasms and active primary malignancies
P2860
Q35820989-11F33E0D-E2A1-4F40-9D31-FB92A8B637E3Q35852574-407360FD-B592-4ADE-AB98-ECB609110BF7Q35865581-448EA63B-E59D-4246-BB55-0E6AE422049AQ35888693-157EE96E-4BDF-49E8-B1B4-970D84A56654Q36148528-DF53BCEF-4D7F-4A8B-A299-5757710EE5E4Q36206601-1D30D32B-F0F3-4DCF-B8C6-087120F2B649Q36301128-339C1F43-E84B-41BB-BF41-D9E58E701D94Q36481199-3656E2C6-07EE-4235-B76D-8E7F3711962EQ36556492-FE396536-653D-41A5-800D-CCB9AE74CF3EQ36689152-1DDCDB6A-48E4-4BDE-BC7D-2CE8050700EBQ36849339-026DF8CE-5260-433E-8D8E-B0C430002A59Q36902825-83F98E3F-B47B-4A29-8CB6-258527CA7E1EQ37088191-A7DBFE69-EDF1-4724-999A-8A6165069357Q37391117-AF6531BF-B587-4546-AF56-41B716D16B2FQ37414672-7727AC60-4A0F-4DFB-BCA1-3528646B4705Q37490193-14A3A23B-7B34-4349-8BEC-54C8945E5CCCQ37682117-7D5F80EA-EB72-4ADC-B5AE-6EEBF3D3F97AQ37822742-6EF8FD45-D47F-49DB-B28E-8DC087CBBF91Q37875193-F138AE36-AD78-40DF-BC90-C285FB6C847BQ38154518-C5CA3DC3-C15E-4613-A9A5-8189B090BC01Q41031177-17B165F0-EE5B-49CD-BCA1-23EF0DC83AD3Q42287525-B3CC10C0-9A06-4D38-8B4D-BE54D8EA384DQ43640246-13DEBE48-606D-4FE1-BFB0-6BC313257580Q45001848-979F8800-66A5-46BA-A6BA-070A4ACEB925Q46216910-693A48BA-9312-4E5D-8729-0B84F745A98AQ46543493-C764071F-0BD8-4600-9D1D-D746912AB856Q46720756-DC89B844-E39D-4AC8-86A2-3528B1E71496Q46965111-9CEDEA2F-4C0B-47EB-B7D5-01D5B3B7D75FQ46965120-CD1E2B7C-218A-4E06-98B5-32D5C2349796Q57636771-214DDBB3-D973-4A99-BD7B-7415E9F189D8
P2860
Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Chronic but not acute graft-ve ...... ve allogeneic transplantation.
@en
Chronic but not acute graft-ve ...... ve allogeneic transplantation.
@nl
type
label
Chronic but not acute graft-ve ...... ve allogeneic transplantation.
@en
Chronic but not acute graft-ve ...... ve allogeneic transplantation.
@nl
prefLabel
Chronic but not acute graft-ve ...... ve allogeneic transplantation.
@en
Chronic but not acute graft-ve ...... ve allogeneic transplantation.
@nl
P2093
P2860
P1476
Chronic but not acute graft-ve ...... ve allogeneic transplantation.
@en
P2093
Adrián Alegre
Ana Sureda
Angel De Leon
Dolores Caballero
Jesús F San Miguel
Jordi Sierra
José A Pérez-Simón
José F Tomás
Rodrigo Martino
P2860
P304
P356
10.1046/J.1365-2141.2003.04237.X
P407
P577
2003-04-01T00:00:00Z